Neurology

Tecfidera (dimethyl fumarate) has been approved by the FDA for the treatment of relapsing forms of multiple sclerosis.

A survey of US neurologists found that a significant minority is unaware of FDA drug safety updates and many who are aware of the updates fail to act on them.

A study including more than half a million Danish children finds that children born to mothers who took the antiepileptic drug valproate during pregnancy were much more likely to develop autism.

A new drug to treat multiple sclerosis has the potential to drive spending increases in the specialty category.

The FDA today approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).

Patients may have questions about their uncomfortable leg sensations.

Patients may have questions about their uncomfortable leg sensations.

Medicinal use of cannabis is gaining acceptance despite a lack of published treatment guidelines.

A study of epilepsy patients who switched from one antiepileptic drug (AED) to another suggests that the switch did not tend to improve seizure control and may have worsened it.

Video from the National Multiple Sclerosis Society with the message, "MS Kills Connection. Connection Kills MS."

Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.

This study discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.

This video summarizes the research findings from ECTRIMS 2012.

EMD Serono, Inc, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced today that the FDA approved Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).

A recent study featured in the American Journal of Pharmacy Benefits examines the role of patient out-of-pocket cost on adherence to disease-modifying therapies for multiple sclerosis.

A new study indicates that starting HRT within 5 years of the onset of menopause is key to producing a neuroprotective effect.

In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.

A new study carried out by Blue Cross and Blue Shield of Minnesota and PBM Prime Therapeutics forecasts that multiple sclerosis specialty drug treatment cost will exceed $50,000 per person per year in 2016.

By the end of this year, it is likely that the FDA will approve more than 20 new specialty medications.